New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
10:47 EDTADP, KOG, IPXL, EWH, PIP High option volume stocks: KOG PIP IPXL ADP EWH
News For KOG;PIP;IPXL;ADP;EWH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 5, 2016
09:23 EDTADPADP weakness creates buying opportunity, says Argus
Subscribe for More Information
February 3, 2016
07:12 EDTADPADP lowers FY16 adjusted EPS growth view to 11%-13% from 12%-14%
As a result of additional selling expenses anticipated from the increased new business bookings forecast and higher expected pressure from unfavorable foreign currency translation, ADP now anticipates adjusted diluted earnings per share growth of 11% to 13% compared with our prior forecast of 12% to 14% growth. This forecast assumes a negative impact of one to two percentage points from unfavorable foreign currency translation. On a constant dollar basis, adjusted diluted earnings per share is expected to increase 12% to 14%, compared with our prior forecast of an increase of 13% to 15%. Consensus $3.25.
07:11 EDTADPADP lowers FY16 revenue growth view to 7% from 7%-8%
Subscribe for More Information
07:02 EDTADPADP reports Q2 EPS 74c, consensus 72c
Reports Q2 revenue $2.8B, consensus $2.81B. Worldwide new business bookings grew 15% for the quarter.
February 2, 2016
15:01 EDTADPADP technical notes before earnings
Subscribe for More Information
14:32 EDTADPNotable companies reporting before tomorrow's open
Subscribe for More Information
09:11 EDTADPADP management to meet with Oppenheimer
Subscribe for More Information
07:36 EDTIPXLImpax receives tentative FDA approval for generic Vytorin ANDA
Impax Laboratories announced that Impax has received tentative approval from the U.S. FDA for its Abbreviated New Drug Application for the generic version of the ezetimibe and simvastatin containing tablets, in 10 mg / 10 mg, 10 mg / 20 mg, 10 mg / 40 mg and 10 mg / 80 mg strengths. "We are pleased to receive tentative approval from the FDA for our generic version of Vytorin tablets," said Fred Wilkinson, President and CEO. "We will continue to work with the FDA to gain final approval upon the expiration of the U.S. patents and associated pediatric exclusivity on April 25, 2017, and are currently planning to be among the first generic products to market."
07:17 EDTADPADP to hold a webinar
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use